RALEIGH, N.C., Nov. 27, 2013 (GLOBE NEWSWIRE) -- LipoScience, Inc. (Nasdaq:LPDX) today announced that Bob Greczyn, Interim President and Chief Executive Officer, and Lucy Martindale, Executive Vice President and Chief Financial Officer, will present at the 25th Annual Piper Jaffray Healthcare Conference at 11:00 A.M. ET on Wednesday, December 4, 2013, in New York City.
The presentation will be webcast live and can be accessed on the Investor Relations section of the corporate website at http://investor.liposcience.com. For those who are not available to listen to the live broadcast, the webcast will be archived for 90 days.
About LipoScience, Inc.
LipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. The company's first proprietary diagnostic test, the NMR LipoProfile® test, measures the number of low-density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 10 million NMR LipoProfile tests have been ordered. LipoScience's automated clinical analyzer, Vantera®, has been cleared by the U.S. Food and Drug Administration (FDA). It requires no previous knowledge of NMR technology to operate and has been designed to dramatically simplify complex technology through ease of use and walk-away automation. The Vantera Clinical Analyzer will be placed with national and regional clinical laboratories.
LipoScience is striving toward the NMR LipoProfile test becoming the preferred choice by physicians for management of cardiovascular disease. For further information on LipoScience, please visit www.liposcience.com and www.theparticletest.com.